CVAC vs. INSM, HCM, BHVN, PBH, ARWR, XENE, CORT, FOLD, IDYA, and PTCT
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Insmed (INSM), HUTCHMED (HCM), Biohaven (BHVN), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
CureVac (NASDAQ:CVAC) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
In the previous week, Insmed had 64 more articles in the media than CureVac. MarketBeat recorded 69 mentions for Insmed and 5 mentions for CureVac. Insmed's average media sentiment score of 0.56 beat CureVac's score of 0.38 indicating that Insmed is being referred to more favorably in the news media.
CureVac has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Insmed received 494 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 65.23% of users gave Insmed an outperform vote while only 51.16% of users gave CureVac an outperform vote.
Insmed has a net margin of -236.74% compared to CureVac's net margin of -463.49%. Insmed's return on equity of 0.00% beat CureVac's return on equity.
CureVac has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
CureVac currently has a consensus target price of $8.33, indicating a potential upside of 114.22%. Insmed has a consensus target price of $56.38, indicating a potential upside of 2.41%. Given CureVac's higher possible upside, research analysts clearly believe CureVac is more favorable than Insmed.
Summary
Insmed beats CureVac on 11 of the 18 factors compared between the two stocks.
Get CureVac News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
